March 13, 2025 - 12:20

The National Institutes of Health (NIH) is making significant cuts to funding for numerous studies focused on understanding vaccine hesitancy and strategies to improve vaccination rates. This decision comes at a time when public health experts emphasize the importance of addressing vaccine skepticism to enhance community immunity and public health outcomes.
In addition to vaccine hesitancy research, there are indications that mRNA vaccine studies may also face funding reductions. mRNA technology has been pivotal in the rapid development of COVID-19 vaccines, and any cuts to this area of research could have far-reaching implications for future vaccine development and pandemic preparedness.
The decision has sparked concerns among researchers and public health advocates, who argue that understanding the roots of vaccine hesitancy is crucial for developing effective communication strategies and interventions. The potential impact on mRNA research raises questions about the future of innovative vaccine technologies that have shown promise in combating infectious diseases.
August 11, 2026 - 07:33
MiTAC Computing Technology USA Corporation Announces Grand Opening of Expanded Newark Office to Drive U.S. Infrastructure GrowthThe expansion is designed to support customer co-innovation and long-term enterprise growth, giving the company more room to develop and test infrastructure solutions tailored to U.S. clients....
August 10, 2026 - 21:56
Build a technology road map for the futureA fresh wave of research is giving police chiefs and public safety officials a clearer picture of what technology will look like in the next decade, and it is not just about body cameras or faster...
August 10, 2026 - 06:32
Can Congress Govern Disruptive Technology?Picture this: you wake up to a frozen bank account because an AI system flagged you as a fraud risk. No human picks up the phone. Another algorithm reviews your appeal. Hours pass. The mistake gets...
August 9, 2026 - 18:04
Microchip Technology (MCHP) Could Be 25% Undervalued As Q1 Results Beat GuidanceThe reaction was immediate. Shares jumped 13.89% in a single session and held onto those gains over the following week, pushing the seven day return to 14%. That bounce reverses a steep 90 day...